Establishment Labs (ESTA) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed Establishment Labs (ESTA) over the past year, gaining 101.2% versus a gain of 51.1%. Over five years, ESTA leads with a -21.3% price change compared with -71.5% for NEOG. Neogen is the larger company by market cap ($2.59 billion vs $1.84 billion), about 1.4 times the size, while Establishment Labs is growing revenue faster (+27.1% vs -2.7%).
On valuation, Neogen trades at a lower forward P/E (31.2x vs 1027.8x for Establishment Labs). Neogen converts more of its revenue into profit, with a net margin of -0.9% versus -24.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESTA | NEOG |
|---|---|---|
| Share price | $61.67 | $11.85 |
| Market cap | $1.84B | $2.59B |
| 1-day change | +1.75% | +1.20% |
| YTD return | -16.84% | +67.53% |
| 1-year return | +51.07% | +101.20% |
| 5-year return | -21.29% | -71.47% |
| Forward P/E | — | 31.18 |
| EPS (TTM) | $-1.30 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $211.08M | $870.40M |
| Revenue growth (YoY) | +27.14% | -2.72% |
| Net income (latest FY) | $-51.06M | $-7.90M |
| Gross margin | 69.32% | 46.93% |
| Operating margin | -18.48% | -2.48% |
| Net margin | -24.19% | -0.91% |
| 52-week high | $97.59 | $14.26 |
| 52-week low | $38.38 | $5.37 |
| Distance from 52-week high | -36.81% | -16.90% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +66.11% | +18.14% |
| Average volume | 427.13K | 3.14M |
| Shares outstanding | 29.80M | 218.31M |
| Employees | 1,004 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEOG has outperformed ESTA by 50.1 percentage points over the past year.
- Neogen is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -24.2 cents for Establishment Labs.
- Establishment Labs grew revenue faster in its latest fiscal year (+27.14% vs -2.72%).
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Health Care · Industrial Specialties · 1,004 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
ESTA vs NEOG FAQ
Which is bigger, Establishment Labs or Neogen?
Neogen (NEOG) is larger, with a market capitalization of $2.59B compared with $1.84B for Establishment Labs (ESTA).
Which stock has performed better over the past year, ESTA or NEOG?
NEOG returned +101.20% over the past 12 months, compared with +51.07% for ESTA (price return, excluding dividends). Past performance does not predict future results.
Are Establishment Labs and Neogen in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Establishment Labs and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Neogen.